

PRECLINICAL TESTING PHASE 1 PHASE 2 PHASE 3 BLA/NDMA/MAA COMMERCIALIZATION

Seven Commercial Products

Palynziq™
(pegvaliase-pqpz) Injection

Brineura™
(cerliponase alfa)

Naglazyme®
(GALSULFASE)

KUVAN®
(sapropterin dihydrochloride) Tablets

ALDURAZYME®
(LARONIDASE)

VIMIZIM®
(elosulfase alfa)

FIRDAPSE™
amifampridine

Vosoritide for Achondroplasia

Valoctocogene roxaparvec for Hemophilia A

Tralesinidase Alfa for MPS IIIB, or Sanfilippo Type B

BMN 290 for Friedreich's Ataxia

PKU Gene Therapy Candidate

Corporate Overview

BioMarin is a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening rare disorders. The company's portfolio consists of seven commercialized products and multiple clinical and pre-clinical product candidates.

General Company Information

- Founded in 1997
- IPO in 1999, NASDAQ ticker BMRN
- More than 2,500 employees worldwide
- Global sales in 70 markets worldwide

BioMarin Facilities


- Headquarters in San Rafael, California
- Manufacturing in Novato, California and Shanbally, Ireland
- Regional offices in Dublin, London, Hong Kong, and Sao Paulo

BioMarin at a Glance

- ~1000% Increase in revenues from 2007 to 2017
- Made the *Forbes* Most Innovative Companies list the past 4 years in a row
- 20th year of scientific innovation
- 7 FDA and EMA approved products
- 3 products currently in late-stage development
- 1st ERT therapy into the CNS via ICV delivery
- 5 years on average from IND to approval for all marketed products
- 177,590,376 shares outstanding

Financial Outlook

Actual and Estimated Revenue 2005-2018



Full Year 2018 Revenue Guidance

(\$ in millions)

Item	Provided 2/22/18
Total BioMarin Revenues	\$1,470 to \$1,530
Vimizim	\$460 to \$500
Naglazyme	\$325 to \$355
Kuvan	\$440 to \$480
Brineura	\$35 to \$55

Selected Income Statement Guidance

(\$ in millions, except percentages)

Item	Provided 2/22/18
Cost of Sales(% of Total Rev.)	20.0% to 21.0%
SG&A Expense	\$575 to \$615
R&D Expense	\$680 to \$710*
Non-GAAP Net Income	\$100 to \$140
GAAP Net Loss	\$(115) to \$(165)

*R&D expense guidance updated August 2, 2018


Executive Management

Jean-Jacques Bienaimé – Chairman and Chief Executive Officer
 Hank Fuchs, M.D. – President, Worldwide Research and Development
 Robert A. Baffi, Ph.D. – Executive Vice President, Technical Operations
 Dan Spiegelman – Executive Vice President and Chief Financial Officer
 Jeff Ajer – Executive Vice President and Chief Commercial Officer

Board of Directors

Jean-Jacques Bienaimé V. Bryan Lawlis, Ph.D.
 Willard H. Dere, M.D. Alan J. Lewis, Ph.D.
 Michael Grey Randy Meier
 Elaine J. Heron, Ph.D. David Pyott
 Robert Hombach Dennis J. Slamon, M.D., Ph.D.

BioMarin Global Footprint



(Information as of 2Q18)